Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/30/2005CA2549509A1 Composition for improving skin, hair and coat health containing flavanones
06/30/2005CA2549426A1 Method of treating fish and crustaceans with a tellurium based immunomodulator
06/30/2005CA2549303A1 Novel sodium channel
06/30/2005CA2549167A1 Inhibitors of hepatitis c virus ns3/ns4a serine protease
06/30/2005CA2549144A1 Novel crystalline forms of 2, 3 dimethyl-8- (2, 6-dimethylbenzylamino) -n-hydroxyethyl-imidazo [1, 2-a] pyridine-6-carboxamide mesylate salt
06/30/2005CA2549117A1 High efficiency fullerene-based radical scavengers
06/30/2005CA2549111A1 Doxepin analogs and methods of use thereof
06/30/2005CA2549098A1 Hiv protease inhibiting compounds
06/30/2005CA2549074A1 Glycosylated steroid derivatives with anti-migratory activity
06/30/2005CA2549072A1 Tricyclic indole hydroxyethylamine derivatives and their use in the treatment of alzheimer's disease
06/30/2005CA2549042A1 Tricyclic benzimidazoles
06/30/2005CA2549031A1 Method for obtaining an enriched population of sirna-expressing cells
06/30/2005CA2549030A1 Tricyclic imidazopyridines for use as gastric secretion inhibitors
06/30/2005CA2549011A1 Compositions comprising two different populations of polymer-active agent conjugates
06/30/2005CA2549001A1 Rifamycin analogs and uses thereof
06/30/2005CA2549000A1 Method for treating neurological disorders
06/30/2005CA2548793A1 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
06/30/2005CA2548790A1 Medicinal compositions and combinations
06/30/2005CA2548781A1 Synthesis of a polymorph of 4-amino-5-chloro-2-methoxy-n-(1-azabicyclo[3.3.1]non-4-yl)benzamide hydrochloride hydrate
06/30/2005CA2548773A1 A treatment for necrotizing enterocolitis
06/30/2005CA2548657A1 Aminobenzimidazoles and benzimidazoles as inhibitors of respiratory syncytial virus replication
06/30/2005CA2548572A1 Hydroxylamine derivatives
06/30/2005CA2548571A1 Diacylhydrazine derivatives
06/30/2005CA2548393A1 Chemokine receptor binding compounds
06/30/2005CA2548391A1 Proline derivatives used as pharmaceutical active ingredients for the treatment of tumours
06/30/2005CA2548388A1 Heterocyclic aspartyl protease inhibitors
06/30/2005CA2548387A1 Sustained release torsemide dosage forms
06/30/2005CA2548300A1 Comt inhibitors
06/30/2005CA2548273A1 Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors
06/30/2005CA2548216A1 Methods of administering water-soluble prodrugs of propofol for extended sedation
06/30/2005CA2548152A1 Compounds for treatment of cell proliferative diseases
06/30/2005CA2548105A1 Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
06/30/2005CA2548074A1 Injectable composition
06/30/2005CA2547820A1 (s)-2-n-propylamino-5-hydroxytetralin as a d3 agonist
06/30/2005CA2547804A1 Novel thiazole derivatives
06/30/2005CA2547764A1 Benzoxazine derivatives and uses thereof
06/30/2005CA2547633A1 Hydronopol derivatives as agonists on human orl1 receptors
06/30/2005CA2547518A1 Quinolines useful in treating cardiovascular disease
06/30/2005CA2547198A1 (3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
06/30/2005CA2547196A1 Combination of (a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and (b) at least one hypusination inhibitor and the use thereof
06/30/2005CA2547195A1 Microemulsion preconcentrate comprising a renin inhibitor
06/30/2005CA2547064A1 New 5,6-dihydropyrin-2-one compounds useful as inhibitors of thrombin
06/30/2005CA2546793A1 Use of stating for the treatment of metabolic syndrome
06/30/2005CA2545760A1 Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
06/30/2005CA2545506A1 Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-ht6 receptor-related disorder
06/30/2005CA2545503A1 Use of sphingosine-1-phosphate (s1p) receptor agonists for the treatment of brain degenerative diseases
06/30/2005CA2545006A1 Biosensors for detecting macromolecules and other analytes
06/30/2005CA2544286A1 Process for producing 2-acylthiophene compound
06/30/2005CA2543076A1 Crystalline forms of (+)- and (-)-erythro-mefloquine hydrochloride
06/30/2005CA2543074A1 Novel 2-(piperazin-1-yl)- and 2-([1,4]diazepan-1-yl)- imidazo[4,5-d]pyridazin-4-one, production and use thereof as medicament for the treatment of diabetes mellitus
06/30/2005CA2539492A1 Topical use of halosalicylic acid derivatives
06/30/2005CA2491338A1 A method for inhibiting the growth of gastrointestinal tract tumors
06/30/2005CA2491141A1 A new composition comprising cs
06/29/2005EP1548033A2 Higly branched soluble glucose polymers
06/29/2005EP1548025A2 Sapogenin derivatives and their use in the treatment of cognitive dysfunction
06/29/2005EP1548024A1 Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
06/29/2005EP1548009A2 Process for the preparation of benzylimidazole derivatives and for losartan
06/29/2005EP1548004A1 Biological low-molecular weight derivatives
06/29/2005EP1547996A1 Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
06/29/2005EP1547650A1 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
06/29/2005EP1547617A1 Arthrodial cartilage extracellular matrix degradation inhibitor
06/29/2005EP1547616A1 Preventive and/or therapeutic drugs for itch
06/29/2005EP1547615A1 Remedy
06/29/2005EP1547614A1 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof
06/29/2005EP1547609A1 Embryo implantation inhibitor
06/29/2005EP1547604A1 Medicinal composition for periodontal pocket administration containing bisphosphonic acid derivative or its salt as the active ingredient
06/29/2005EP1547603A2 Compositions and methods for use in targeting vascular destruction
06/29/2005EP1547602A1 External preparation for inhibiting keloid formation
06/29/2005EP1547601A1 Coating method
06/29/2005EP1547600A1 Female hormone-containing patch
06/29/2005EP1547599A1 Transparent eye drops containing latanoprost
06/29/2005EP1547598A1 NOVEL USES OF PROSTAGLANDIN D sb 2 /sb , PROSTAGLANDIN D sb 2 /sb AGONIST AND PROSTAGLANDIN D sb 2 /sb ANTAGONIST
06/29/2005EP1547597A2 Use of adatanserin for the treatment of neurodegenerative conditions
06/29/2005EP1547596A1 Medicinal composition and method for treating malignant tumor and utilization thereof
06/29/2005EP1547595A1 Patch for transdermal administration
06/29/2005EP1547594A1 Preventive or remedy for bedsore
06/29/2005EP1547593A1 Medicinal composition
06/29/2005EP1547592A1 Intranasal formulation of rotigotine
06/29/2005EP1547591A1 Food improving blood flow
06/29/2005EP1547590A1 Melanin extinguisher
06/29/2005EP1547589A1 Pasting agent
06/29/2005EP1547588A1 Soft capsule preparation
06/29/2005EP1547587A1 Agent for reducing side effects of diclofenac
06/29/2005EP1547586A1 Hypogastric and/or perineal pain-relieving agent
06/29/2005EP1547585A1 Therapeutic agent for rheumatism containing benzamide derivative as active ingredient
06/29/2005EP1547584A1 Particulate product comprising pantethine
06/29/2005EP1547582A1 Method of producing lipid complexed camptothecin-carboxylate
06/29/2005EP1547580A1 Loading of a camptothecin drug into colloidal nanoparticles
06/29/2005EP1547579A1 Adhesive gel composition for iontophoresis preparation and process for producing the same
06/29/2005EP1547578A2 Use of a steroidal or non-steroidal EcR receptor ligand in a cosmetic or dermatological composition for maintaining the skin homeostasis
06/29/2005EP1547577A1 Antiaging composition
06/29/2005EP1547474A1 Functional foods/drinks containing antiallergic component
06/29/2005EP1546377A2 Methods and compositions to treat pain and painful disorders using 9949, 14230, 760, 62553, 41897, 47174, 33408, 10002,16209, 314, 636, 27410, 33260, 619,15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 9569 or 13424 molecules
06/29/2005EP1546375A2 Nucleic acids, polypeptides, and methods for modulating apoptosis
06/29/2005EP1546369A2 Diagnosis and treatment of diseases arising from defects in the tuberous sclerosis pathway
06/29/2005EP1546341A1 Mipp1 homologous nucleic acids and proteins involved in the regulation of energy homeostatis
06/29/2005EP1546216A2 Methods of drug delivery using sulphated chitinous polymers
06/29/2005EP1546199A2 Novel chemokine-like polypeptides
06/29/2005EP1546189A2 Novel compositions and methods for the treatment of immune-related diseases
06/29/2005EP1546182A2 Compositions and methods for the diagnosis and treatment of tumor
1 ... 4635 4636 4637 4638 4639 4640 4641 4642 4643 4644 4645 4646 4647 4648 4649 4650 4651 4652 4653 4654 4655 ... 7860